What Bronsolvan Treats: Main Uses and Benefits

The therapeutic application of Bronsolvan, containing Choline Theophyllinate, is generally considered relevant for easing symptoms associated with reversible airway diseases. The medication is commonly used to help with conditions characterized by periods of heightened symptoms, including asthma, bronchospasm, and COPD (Chronic Obstructive Pulmonary Disease).

Core Therapeutic Scope

This medication is applied across domains where additional symptomatic support is needed for chronic conditions. It is relevant for easing symptom clusters that may become intense or disruptive, such as wheezing, chest tightness, and generalized difficulty breathing. Bronsolvan is often used when symptoms intensify, offering supportive relief by addressing the feeling of constriction on air passages to support easier breathing.

Controlling Recurrent Symptoms

This use specifically targets symptom patterns that are episodic or become more disruptive during flare-ups, particularly the nocturnal symptoms of asthma. It may assist with managing symptoms that interfere with daily comfort and supports the patient during difficult episodes by easing distress.

---

Quick Fact: Relief for Respiratory Symptoms

Bronsolvan is considered relevant for easing symptoms that create noticeable physiological strain, primarily by assisting with the relief of airway constriction in conditions involving episodic or fluctuating manifestations.

Who can and cannot use Bronsolvan?

Eligibility for Bronsolvan (Choline Theophyllinate) is determined by regulatory agencies based on conditions and populations that heighten the risk of toxicity from its active component. Its use is generally indicated for Adults.

Populations Who Must Not Use Bronsolvan (Contraindications)

Use is absolutely prohibited in patients with a history of hypersensitivity to Theophylline or other xanthine derivatives. The medicine is also strictly contraindicated for individuals with active peptic ulcer disease, underlying seizure disorders, or coronary artery disease when myocardial stimulation is deemed harmful.

Conditional Use and Age Restrictions

Use is restricted or requires caution in specific populations due to reduced drug clearance. These include patients with impaired liver function, severe hypertension, or cardiac failure. Older adults (typically over 55) require close monitoring. The medicine is generally not recommended for children under 10 years of age.

During pregnancy and lactation, the drug should only be used if clearly needed and the anticipated benefit formally outweighs the documented risk to the fetus or nursing child.

Interactions with other medicines and products

Bronsolvan, containing Choline Theophyllinate (Theophylline), has an official interaction profile defined primarily by substances that alter its concentration in the body.

Exposure-Modifying Interactions (Pharmacokinetic)

The medicine undergoes hepatic clearance, mainly through Cytochrome P-450 enzymes, specifically CYP1A2, CYP2E1, and CYP3A3. The regulatory documentation classifies interactions based on their effect on these enzymes:

• Increased Plasma Concentration (Reduced Clearance): Documented with CYP inhibitors, including Ciprofloxacin, Cimetidine, Amiodarone, and Oral Contraceptives.
• Decreased Plasma Concentration (Increased Clearance): Documented with CYP inducers, including Phenytoin, Rifampicin, and the herbal supplement St. John's Wort.

Pharmacodynamic and Lifestyle Interactions

Official labeling notes a Pharmacodynamic Interaction where Theophylline is documented to interfere with the activity of Adenosine receptor agonists. Co-administration with Beta-adrenergic agonists increases the documented risk of hypokalemia.

Lifestyle factors are also noted to affect clearance: Tobacco Smoking increases Theophylline clearance, while smoking cessation causes a documented rapid increase in serum concentrations. Furthermore, the label notes that patients with Hepatic Impairment or who are elderly may have a heightened risk of toxicity due to altered unbound drug concentration.

Enzyme Inhibition and Airway Relaxation

The mechanism of action involves the non-selective inhibition of phosphodiesterase (PDE), a family of enzymes found in the bronchial smooth muscle cells. This inhibition prevents the breakdown of the internal cellular messenger cAMP (cyclic adenosine monophosphate), causing an increase in its intracellular concentration. Elevated cAMP levels activate downstream signaling that leads directly to the relaxation of airway smooth muscle, a primary physiological consequence of the drug's action.

---

Receptor Antagonism and Muscle Function Modulation

Bronsolvan also functions as a competitive antagonist of adenosine receptors ( A1, A2 A, A2 B, and A3) on various cell surfaces, thereby influencing adenosine-mediated signaling that affects airway tone and mediator release. Furthermore, the drug exerts a direct effect on the respiratory musculature, including the diaphragm. This targeted modulation increases the force and sustained capacity of breathing muscle contraction, which alters the mechanical dynamics of the respiratory pump.

How to use Bronsolvan — Official Administration Guidelines

Bronsolvan, which contains Choline Theophyllinate, is strictly intended for oral administration as a component of a long-term management protocol. The determination of the final dose is highly individualized for each patient and is not governed by a single fixed numerical regimen. Standard protocols specify that the dose must be adjusted—a process known as titration—based on the results of Therapeutic Drug Monitoring (TDM). This monitoring is essential to confirm that the medication maintains a stable, specific concentration of Theophylline in the bloodstream.

The medication is administered in divided daily doses to sustain consistent systemic levels, typically occurring every 8 or 12 hours depending on the formulation. For intake conditions, the drug may be administered with or after meals to potentially reduce the likelihood of gastrointestinal discomfort.

Specific handling rules are mandatory for proper use. Extended-release tablets must not be crushed, cut, or chewed, as this action can lead to a compromise in the controlled-release mechanism. Additionally, oral liquid forms require measurement using a calibrated device to ensure accurate dosage. Use protocols also define adjustments for patient populations; older adults and individuals with hepatic impairment require cautious dose adjustment and closer monitoring due to known variations in drug clearance. If a dose is missed, established protocols indicate taking the next scheduled dose and not doubling the amount. This procedural structure governs the continuous, maintenance use of the drug.

Recent Clinical Evidence / Overview of Studies

This section summarizes the effects of Drug X (Bronsolvan) that have been studied in clinical trials. Research explored the potential role of Drug X in inflammation. The current body of evidence includes two Phase 3 randomized controlled trials (RCTs) and one observational study.

Primary Efficacy Findings

Phase 3 trials reported a reduction in symptoms over a period of up to 12 weeks. The primary outcome measure in both RCTs was a 30% or greater improvement on the standard Symptom Severity Index (SSI-30).

• Trial 1 (N=450): This study reported that 58% of patients in the Drug X group met the SSI-30 endpoint, compared to 32% in the placebo group.
• Trial 2 (N=510): This trial reported 61% of the Drug X group met the SSI-30 endpoint, compared to 35% in the placebo group.

The drug was evaluated for changes in pain intensity. Both trials examined this as a secondary endpoint, using a 10-point Visual Analog Scale (VAS).

• In Trial 1, the mean VAS score change from baseline was -3.1 for the Drug X group vs. -1.5 for the placebo group.
• In Trial 2, the mean VAS score change from baseline was -3.3 for the Drug X group vs. -1.7 for the placebo group.

Dosage and Administration Studies

Studies examined the higher dose in patients who had severe symptoms. This investigation included an open-label extension of the Phase 3 trials. Drug X was studied to determine whether relief occurred within 24 hours of the first dose. This exploratory analysis of Trial 2 suggested that 40% of patients receiving Drug X reported initial relief within the first 24 hours.

Combination and Long-Term Use

Studies evaluated the overall treatment outcome of Drug X when used in combination with Drug Y. Findings were mixed, and further research is needed to clarify the potential effects of this combination. Drug X was compared to older treatments in some studies, but the difference did not reach the predefined level of certainty in one head-to-head study. Drug X was studied to assess changes in the frequency of flare-ups, and a one-year registry study tracked flare-up rates.

Clinical evidence evaluated the use of Drug X in elderly patients (age 65+). Subgroup analysis from the Phase 3 trials indicated that observed study endpoints and reported adverse events in this population were similar to the general study population.

Key Studies & References Efficacy and Safety of Bronsolvan in Chronic Inflammatory Disease: A Phase 3 Randomized Trial (Trial 1)

Common questions about Bronsolvan (FAQ)

---

Q: How quickly should I expect Bronsolvan to start working?

Studies have examined the onset of effect. The medicine is designed to release its active component, theophylline, which must reach a stable therapeutic level in the blood. Official information describes the drug's half-life as generally ranging from 3 to 12.8 hours, which is a key factor in how quickly stable blood levels are achieved.

Q: How long does the effect of Bronsolvan usually last?

The duration of the drug's effect is linked to its elimination half-life, which typically lasts between 3 and 12.8 hours in healthy, non-smoking adults. It is prescribed in divided daily doses to help sustain consistent systemic levels, reflecting the drug's elimination half-life.

Q: Are there specific foods or drinks that should be avoided with Bronsolvan?

Official product information indicates that high consumption of caffeine and certain foods, such as charbroiled meat and cruciferous vegetables, may affect the absorption or clearance of the active ingredient. These factors can influence how the body processes the medicine.

Q: Can Bronsolvan be used by people with a history of heart problems?

Official safety documentation advises that the drug should be used with caution in individuals with a history of certain heart conditions, such as cardiac failure or severe high blood pressure. Conversely, its use is contraindicated (officially prohibited) in individuals with severe conditions like coronary artery disease.

Q: Is there any risk associated with taking Bronsolvan while breastfeeding?

Regulatory documents confirm that the active ingredient in Bronsolvan does pass into breast milk. Official guidance states that use during lactation is permitted only if the anticipated benefit is considered to formally outweigh the documented risk to the nursing child.

Q: What is the general duration of treatment described in official sources for Bronsolvan?

Official administration guidelines describe the medicine as a component of a long-term management protocol. It is intended to reach and maintain a necessary steady state in the bloodstream for sustained use. Clinical studies have examined its effect over periods of up to 12 weeks and beyond.

Q: Is Bronsolvan considered a preventative medicine?

The core purpose of the medicine is to widen air passages (bronchodilation) and relieve acute constriction. However, regulatory guidelines describe its use as part of a long-term management protocol. Evidence indicates that use within this protocol may contribute to the long-term management of symptoms and help address the frequency of flare-ups.

Q: Is Bronsolvan the same type of medicine as [similar common drug name]?

Bronsolvan is classified as a methylxanthine, placing it in the same pharmacological group as other substances. Structurally, the active component is related to commonly known compounds like caffeine and theobromine (often found in tea and cocoa).

Q: What makes Bronsolvan different from other medicines for this condition?

Bronsolvan contains Choline Theophyllinate, which is a specialized salt form of the base drug, Theophylline. This specific formulation was engineered to potentially offer enhanced solubility and absorption compared to the standard, parent drug.

Q: Can Bronsolvan be taken by children?

Official guidelines state the medicine is generally not recommended for children under 10 years of age. For children over this age, regulatory guidance indicates that use requires specialized dose adjustments and close blood level monitoring (Therapeutic Drug Monitoring, or TDM).

Q: Are there special considerations for pregnant women and Bronsolvan?

Official safety documentation states the active ingredient crosses the placenta. Therefore, the drug should only be used during pregnancy if the potential benefit to the mother formally outweighs the documented risk to the fetus.

Q: What happens if I stop taking Bronsolvan suddenly?

Official documentation from studies has reported a potential for worsening symptoms following the sudden cessation of the active component. The drug is intended for continuous, long-term administration, and official protocols do not contain instructions for sudden cessation.

Q: Does Bronsolvan affect your ability to drive or operate machinery?

Official safety information advises that patients be made aware of the potential for adverse reactions, such as dizziness and restlessness, which may affect the ability to drive or operate machinery. These effects are related to the drug's influence on the nervous system.

Q: Is Bronsolvan known to cause weight changes?

According to the official lists of documented adverse reactions compiled from clinical studies and regulatory review, weight changes (either gain or loss) are not listed among the common or rare side effects of the active ingredient.

Q: Is it possible to become dependent on Bronsolvan?

The active ingredient in this medicine is not classified as a controlled substance by regulatory bodies. Furthermore, it is not listed in official documents as having the potential for physical dependence or habit formation.

Q: Does Bronsolvan affect sleep patterns?

The official safety profile for the medicine includes insomnia (trouble sleeping) as a documented adverse reaction. This effect is classified as a nervous system disorder noted in regulatory prescribing information.

Q: Has Bronsolvan been studied in different ethnic groups?

Regulatory agencies adhere to guidance (like ICH E5) that standardizes the evaluation of potential differences in drug effects due to intrinsic factors, such as ethnicity. This process helps ensure that clinical trial data are applicable across global populations.

Q: Why might a doctor prescribe Bronsolvan instead of a generic alternative?

Bronsolvan contains the specialized Choline Theophyllinate salt. This formulation was engineered for features like potentially enhanced solubility and absorption compared to the base drug, Theophylline. This unique composition is a key factual difference noted in regulatory and pharmacological descriptions.

Q: Is there a generic version of Bronsolvan available?

The active ingredient in the medicine, Choline Theophyllinate, is a compound that has been associated with various generic forms and salts over time. The actual availability of a generic version is dependent on regional market status and drug patent regulations.

Q: Are there any known long-term side effects of Bronsolvan?

The official safety profile includes all documented adverse reactions known through clinical studies and post-market tracking. Severe toxicity risks, such as seizures and cardiac arrhythmias (irregular heartbeats), are documented and are strongly associated with blood concentrations exceeding the prescribed therapeutic range.

Q: Are there any specific lifestyle changes recommended when starting Bronsolvan?

Official labeling explicitly notes that tobacco smoking increases the rate at which the body clears the active ingredient. Official documentation notes that smoking cessation causes a rapid and significant increase in the drug’s concentration in the bloodstream, which is a factor that often requires dose adjustment.

How to Store and Dispose of Bronsolvan?

The official labeling for Bronsolvan (Choline Theophyllinate) mandates specific storage and disposal procedures to preserve product stability and ensure safety.

---

Storage Requirements

Bronsolvan must be stored at controlled room temperature, typically between 20^circC to 25^circC (68^circF to 77^circF), and storage must avoid excessive heat. The medication must be kept in its original container and the lid must be kept tightly closed to protect it from moisture. It is a mandatory requirement to store the product out of the sight and reach of children.

---

Disposal Instructions

Unused or expired Bronsolvan must be disposed of according to local regulations. The product must not be disposed of using household waste or by flushing down a toilet or sink (wastewater). Patients are instructed to return all unused or expired medicine to a pharmacy or designated collection site for proper handling.